Come up with a name for your new list and we'll add to it:
Histide raised a round of funding on November 10, 2014. Investors include
PARTER Capital Group.
Histide is pioneering Recoding Therapeutics, a novel therapy using non-mutagenic extracellular technologies to direct cell fate. Based on the universal understanding of the mechanisms underlying mamma…